Cardiovascular-kidney-metabolic (CKM) health — why we look at these together

About this guide

Many of our patients come in with a list: diabetes, high blood pressure, high cholesterol, a bit of excess weight, perhaps a low-grade kidney reading. Until recently, each of these was often treated as if it were a separate issue, sometimes by separate specialists. The result was a fragmented plan, a long list of medications, and — for many patients — a nagging sense that no one was looking at the whole picture.

The American Heart Association’s 2023 Presidential Advisory on cardiovascular-kidney-metabolic (CKM) health changed that framing. It argues, on the basis of an enormous body of evidence, that these conditions aren’t parallel and independent — they are different expressions of a single underlying process. The drivers overlap, the complications overlap, and — critically for our practice — several of the most effective treatments now work across all of them.

This guide is written for patients who recognise at least a few of those labels on their chart. It covers:

• What CKM syndrome actually is, and why the “cluster” matters
• How we assess it in primary care — the CKM-informed visit
• The medications that work across multiple components at once
• The lifestyle foundations that hold the whole thing together
• How we prioritise when you have several of these things at once

It sits alongside our existing guides on what is diabetes, cholesterol and statins, hypertension management, and chronic kidney disease — this piece is the integration layer on top of those.

What is CKM syndrome?

CKM syndrome is a clinical framework describing the interconnected relationships between:

• Excess or dysfunctional body fat — not just BMI, but where the fat is stored and how metabolically active it is
• Metabolic risk factors — high blood glucose or diabetes, high blood pressure, abnormal lipids
• Chronic kidney disease — reduced filtering function and/or protein leak in the urine
• Cardiovascular disease — coronary artery disease, heart failure, stroke, peripheral vascular disease, and atrial fibrillation

The central clinical insight is that these don’t run in parallel. Dysfunctional adiposity drives insulin resistance. Insulin resistance drives diabetes and hypertension. Diabetes and hypertension drive kidney damage. Kidney damage drives cardiovascular risk. Cardiovascular disease drives heart failure. Each step amplifies the next, and the whole system reinforces itself.

Treating just one component — say, lowering blood sugar but ignoring the kidney, weight, or blood pressure — misses most of the leverage. A well-designed plan addresses the cluster.

Why these systems drive each other

It helps to understand a few of the mechanisms, even in broad strokes:

• Dysfunctional fat tissue — not all body fat is equal. Visceral fat (the fat inside the abdomen, around the organs) and ectopic fat (fat stored in the liver, muscle, pancreas, and heart) are metabolically active in ways that subcutaneous fat is not. They release inflammatory molecules and free fatty acids into the bloodstream, which interfere with how insulin works elsewhere in the body.
• Insulin resistance — the earliest measurable biochemical step. The body needs higher and higher insulin levels to do the same job, and the elevated insulin itself drives sodium retention (raising blood pressure), lipid abnormalities (raising triglycerides and lowering HDL), and further fat storage.
• Activation of the renin-angiotensin-aldosterone system (RAAS) — the hormone system regulating blood pressure and fluid balance becomes overactivated, raising blood pressure, damaging small vessels, and promoting kidney injury.
• Chronic low-grade inflammation — a persistent background level of inflammatory signalling injures blood vessel walls, accelerating atherosclerosis.
• Oxidative stress — an excess of reactive molecules damages cells, including the filtering units of the kidney and the endothelial lining of blood vessels.
• Cardiorenal cross-talk — a failing heart reduces kidney perfusion, and kidney dysfunction drives fluid retention and worsens heart failure. This is a two-way street rather than a one-way dependency.

None of this requires deep biology to appreciate. The practical point: the things you can do (or medications you can take) that improve one part of this system often improve the others too. That’s the core of why the CKM framework has real clinical utility.

The CKM stages — where you are on the spectrum

The AHA framework organises CKM into five stages. Most patients aren’t labelled with a stage number in everyday practice, but understanding the ladder helps you see why we assess what we assess.

Stages aren’t one-way. With good management — particularly in early stages — patients can move in the right direction. Many of our patients with stage 1 or early stage 2 regress with targeted lifestyle change and appropriately-chosen medication.

An important Asian-specific point: the adiposity cut-offs that define Stage 1 are lower in Asian populations than in European populations. A BMI of 23 (not 25) already marks increased risk in most Asian groups; waist circumference thresholds are 90 cm for men and 80 cm for women. This is why we pay attention to weight and waist even in patients who don’t look “overweight” by Western standards.

Risk prediction — the PREVENT framework

Alongside the CKM staging, the AHA released the PREVENT (Predicting Risk of cardiovascular disease EVENTs) risk equations in 2023. They estimate 10- and 30-year risk of cardiovascular disease and were designed to replace older tools like the Pooled Cohort Equations.

What’s different about PREVENT:

• Applicable to a much broader age range (30 to 79 years)
• Includes kidney function (eGFR) as an input, which earlier calculators didn’t
• Allows albuminuria and HbA1c as optional inputs when available, making it more sensitive for CKM-heavy patients
• Removed race as a risk multiplier — a significant methodological shift
• Provides a 30-year risk number in addition to the usual 10-year, which is especially useful for younger patients where a 10-year risk number looks reassuring but the long-run trajectory is concerning

In Singapore, we continue to use the SG-FRS-2023 (Singapore-modified Framingham Risk Score) as our primary cardiovascular risk calculator, because it’s calibrated to local event rates. PREVENT is a useful complement, particularly in younger patients and in those where kidney function is in question. We may use either — or both — in discussion with you.

Details on targets and statin decisions sit in our cholesterol and statins guide.

What this changes in your visits with us

The CKM framework shifts the shape of a chronic-disease review from a single-organ check-up into a whole-person one. A CKM-informed visit typically covers:

• Weight, BMI, and waist circumference — because adiposity is upstream of much of the rest
• Blood pressure, ideally with home monitoring context
• Fasting glucose or HbA1c — and any family history of diabetes
• Lipid panel — LDL, HDL, triglycerides, non-HDL
• eGFR and urine albumin-to-creatinine ratio (UACR) — the urine test especially matters, because significant albuminuria can exist with a normal eGFR
• Smoking status and any vaping use
• Sleep quality and screening for obstructive sleep apnoea — one of the more under-recognised CKM drivers
• A short check on mood, stress, and social context — because all three affect the adherence and lifestyle pieces
• Review of vaccination status — flu, pneumococcal, shingles, hepatitis B (especially if moving toward advanced CKD), COVID

Not everything gets checked at every visit. But over a year, this list is what we’re tracking — and it’s also the list you can use to prompt a conversation if something hasn’t been reviewed in a while.

Why we cross-check. If your blood pressure is the headline, we still ask about glucose and kidney function — because hypertension is often an early CKM signal and the kidneys rarely stay completely untouched when blood pressure is high. The same logic runs the other way for any of the components. In practice, running one test in isolation gives you a misleadingly narrow view.

Medications that work across the cluster

The last decade has produced several medication classes that genuinely work across multiple CKM components at once. A brief tour, useful context for why we sometimes recommend what we do:

SGLT2 inhibitors (dapagliflozin — Forxiga; empagliflozin — Jardiance)

Originally developed as diabetes medications, SGLT2 inhibitors now have proven benefit in:

• Diabetes — lower glucose, modest weight loss, low hypoglycaemia risk
• Heart failure — reduce hospitalisations and mortality in heart failure with both preserved and reduced ejection fraction
• Chronic kidney disease — slow kidney function decline, reduce progression to kidney failure, regardless of whether the patient has diabetes
• Blood pressure — a small but consistent reduction
• Weight — typically 2–3 kg

For a single medication class to act on four CKM components is unusual, and this is part of why the landscape has shifted.

GLP-1 receptor agonists (semaglutide — Ozempic/Wegovy; dulaglutide — Trulicity; liraglutide — Victoza)

Originally for diabetes, now used well beyond it:

• Diabetes — strong glucose reduction, low hypoglycaemia risk
• Weight management — 10–17% body weight loss at higher doses (Wegovy-branded semaglutide is registered specifically for weight)
• Cardiovascular risk — reduction in major cardiovascular events in high-risk patients, including those without diabetes
• Emerging kidney benefit — the recent FLOW trial (semaglutide) showed a 24% reduction in the composite kidney outcome in patients with CKD and type 2 diabetes
• Metabolic-associated steatotic liver disease (MASLD/MASH) — improvement in liver fat and fibrosis

Tirzepatide (Mounjaro, Zepbound)

A newer dual GIP/GLP-1 receptor agonist. Even greater weight loss (often 18–22%) than GLP-1 alone, with strong glucose effects and emerging CV data. Registration and availability in Singapore continue to evolve.

Finerenone (Kerendia)

A non-steroidal mineralocorticoid receptor antagonist. Reduces both cardiovascular and kidney outcomes in patients with diabetic kidney disease on top of ACEi/ARB + SGLT2 inhibitor. Availability in Singapore remains limited at present — we’d discuss this as a later add-on in the right patient.

ACE inhibitors and ARBs

The foundational blood-pressure-lowering class for anyone with albuminuria, kidney disease, heart failure, or post-heart-attack. Benefits extend across blood pressure, kidney protection, and cardiovascular event reduction.

Statins

The cornerstone of lipid lowering with established CV mortality benefit. Safe in kidney disease with dose adjustment in later stages. Details in our cholesterol and statins guide.

Metformin

The first-line diabetes medication for most patients, with decades of safety data, some cardiovascular benefit, low hypoglycaemia risk, and minimal cost.

The polypharmacy question

A patient with advanced CKM might end up on: an ACEi or ARB, a statin, metformin, an SGLT2 inhibitor, a GLP-1 RA, possibly finerenone, possibly a beta-blocker or calcium channel blocker, possibly aspirin. That is genuinely a lot of tablets.

The fair framing: each of those has strong trial evidence for your specific risk profile. They are not “extra”; they each protect a meaningful component of the CKM cluster. But the practical reality — cost, timing, tolerability, pill burden — needs discussion. We’d rather you were on a simpler regimen that you actually take than a theoretically optimal one that lives in your medicine cabinet unused.

Our usual approach: start with the most impactful single agent for your picture, build up one step at a time, review at 2–3 months, and adjust. We’ll talk through what each drug is doing and why; ask if you’re not sure.

Lifestyle — the foundation under all of it

Medication gets a lot of the air time in CKM conversations, but the lifestyle foundation is what the medication is built on. Without it, medication yields smaller gains and more side effects.

Food pattern

A Mediterranean or DASH-style pattern has the strongest evidence for CKM risk reduction — but these have to be adapted to local eating.

• More plants — vegetables, fruit, wholegrains, beans, nuts, and seeds
• Healthy fats — olive oil, nuts, seeds, fatty fish
• Less refined carbohydrate — white rice and bread are staple in our diets; reducing portion size and mixing in brown rice, quinoa, or oats shifts the glycaemic load
• Moderate protein — fish, tofu, lean meat, eggs, dairy
• Less processed and ultra-processed food — which quietly drive sodium, sugar, and saturated fat upward
• Less added sugar and sugar-sweetened drinks — kopi-si kosong is a practical lever
• Less saturated fat — particularly in processed foods
• Reasonable salt — aiming for under 2 g of sodium per day; Health Promotion Board’s online sodium tool is genuinely useful in Singapore because hawker-dish sodium varies so much between vendors

Physical activity

• 150–300 minutes per week of moderate-intensity activity — brisk walking, cycling, swimming — plus 2 resistance sessions a week, are the aerobic and strength targets
• Activity works across the cluster: it lowers blood pressure, improves insulin sensitivity, reduces lipid abnormalities, supports weight, improves sleep, and reduces cardiovascular events independently of weight change
• Movement matters even when it doesn’t produce weight loss — “not thin yet” is not a reason to stop

Weight

• A 5–10% weight reduction is clinically meaningful across all CKM components
• 15% or more — increasingly achievable with GLP-1 RAs and tirzepatide — unlocks additional benefit including possible remission of type 2 diabetes and meaningful improvement in MASLD
• Stable weight loss over 12–18 months beats rapid loss followed by regain

Sleep

• Aim for 7–9 hours per night
• Screen for obstructive sleep apnoea in anyone with hypertension, heart failure, atrial fibrillation, or significant obesity — OSA both drives CKM risk and is readily treatable
• Shift work and chronic sleep restriction are under-appreciated CKM amplifiers

Stress and mental health

Chronic stress, untreated anxiety or depression, and social isolation all drive CKM risk through cortisol, sympathetic activation, and behaviour (eating, sleep, activity). We often include a brief mood screen in CKM-informed reviews; where indicated, we’d refer to psychological support.

Smoking and alcohol

• Smoking cessation is the single most impactful change at any age. The I Quit national programme and pharmacotherapy (nicotine replacement, varenicline, bupropion) are available — ask at your visit.
• Alcohol within moderate limits is acceptable for most people (no more than 2 standard drinks per day for men, 1 for women). Less is better for blood pressure and liver health.

Shared decision-making when priorities compete

In real practice, CKM patients present with trade-offs. A few common situations and how we think about them:

• A frail older patient with CKD + HTN + DM. We may prefer slightly softer targets (BP <140/90, HbA1c up to 8%, LDL <2.6) rather than the tightest numbers, because the downsides of over-medication — hypotension, falls, hypoglycaemia — carry real weight at that stage of life.
• A young patient with early stage 2 CKM (prediabetes, mild hypertension, borderline lipids). The biggest gains here usually come from sustained lifestyle change and judicious single-agent medication. Starting five drugs at once is usually the wrong move; starting two, reviewing at 3–6 months, and adding more if needed is usually the right one.
• A patient who genuinely can’t tolerate multiple medications. Drug sequencing and class selection matter. We’d often start with the agent that gives the biggest single benefit for the most prominent risk — an SGLT2 inhibitor for someone with diabetes + CKD; a GLP-1 RA for someone where weight is the dominant driver; an ACE inhibitor for someone with albuminuria or heart failure.
• A patient in acute life transition — recent bereavement, job change, caregiver burden. This is often the wrong time to change half their medication list. We’d revisit in a few months.

Shared decision-making isn’t a slogan in CKM care; it’s a practical necessity. Different patients rationally weigh different priorities, and our plan should reflect that.

When specialist input helps

Most CKM-focused care is well-managed in primary care. Shared or specialist care becomes valuable when:

• Advanced CKD — G3b and beyond (see our CKD guide)
• Established cardiovascular disease requiring specialist follow-up — recent heart attack, significant heart failure, complex arrhythmias, severe peripheral vascular disease
• Diabetes requiring complex regimens — e.g. type 1, brittle type 2, pump or continuous glucose monitoring decisions
• Significant obesity being considered for bariatric / metabolic surgery — eligibility criteria and pre-assessment usually need endocrinologist or bariatric team input
• Secondary or resistant hypertension — worth investigating when standard regimens don’t achieve control
• Unusual or autoimmune contributors — SLE, vasculitis, primary renal disease
• Complex lipid disorders — familial hypercholesterolaemia, severe hypertriglyceridaemia requiring specialist lipid clinic input

Shared care doesn’t mean we hand you over; it means we coordinate with the specialist while continuing to provide your core longitudinal care. Most patients benefit from having one doctor who holds the whole picture — that’s often the role of a family physician.

The Singapore context

• Healthier SG Chronic Tier (February 2024 onwards) — for enrolled patients, common chronic medications (including ACEi/ARBs, statins, metformin, selected SGLT2 inhibitors and GLP-1 RAs) are available at prices close to polyclinic rates. This is designed for longitudinal chronic-disease care with your chosen GP.
• Community Health Assist Scheme (CHAS) — means-tested subsidies for consultations and selected medications at participating GP clinics. More at chas.sg.
• MediSave — for chronic disease consultations and selected medications, up to the annual limit (currently $500, rising to $700 / $1,000 from January 2027).
• Healthier SG — the national preventive framework emphasises exactly the CKM-informed whole-person review. Being enrolled with us means we can track the cluster over time rather than see you episodically.
• Allied health and counselling — accessible through Primary Care Networks and the wider MOH preventive care ecosystem.

The bottom line

If you have one CKM condition, you almost certainly have early features of others. If you have three or four, you are in the cluster — and the cluster responds meaningfully to coordinated care. Our job in primary care is to hold that whole picture: track the numbers that matter, flag the trajectories we don’t like, pick the medications that work across multiple components, support the lifestyle foundation, and match intensity to your individual circumstances and preferences.

That’s not “more medicine.” It’s actually more targeted medicine, with fewer blind spots.

Get in touch

Joo Chiat — 172 Joo Chiat Road, #01-01, Singapore 427443 · Tel 6920 1952

Punggol — 658 Punggol East, #01-04, Singapore 820658 · Tel 6312 4589

Email — admin@ktmc.sg

References

Framework and staging

• Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635. doi.org/10.1161/CIR.0000000000001184
• Ndumele CE, Neeland IJ, Tuttle KR, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023;148(20):1636–1664.

Risk prediction

• Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) Equations. Circulation. 2023;149(6):430–449.
• Singapore-modified Framingham Risk Score 2023 (SG-FRS-2023). cvd.clinicaltools.mohtgroup.com

Pharmacotherapy across CKM

• Packer M, Anker SD, Butler J, et al. (EMPEROR-Preserved). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451–1461.
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. (DAPA-CKD). Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436–1446.
• EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117–127.
• Wilding JPH, Batterham RL, Calanna S, et al. (STEP-1). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.
• Perkovic V, Tuttle KR, Rossing P, et al. (FLOW Trial). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391:109–121.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. (SURMOUNT-1). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
• Bakris GL, Agarwal R, Anker SD, et al. (FIDELIO-DKD). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219–2229.

Asian-adjusted adiposity thresholds

• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.

National programmes

• Ministry of Health, Singapore. Healthier SG and Chronic Tier information. healthiersg.gov.sg
• Community Health Assist Scheme. chas.sg
• Health Promotion Board Singapore. Food Composition Online Search. focos.hpb.gov.sg

This information is for general education only and is not a substitute for medical advice. CKM management is individualised to the pattern and severity of each person’s risk factors, preferences, and life circumstances — please speak with our team about what’s right for you. v1.0 · April 2026 · Review due April 2028.